Sai Life Sciences Delivers Strong Q2 FY27 Results with 23% Revenue Growth
Sai Life Sciences Ltd · Press Release · 06 Nov 2026, 5:43 am
Sai Life Sciences Delivers Strong Q2 FY27 Results with 23% Revenue Growth Sai Life Sciences reported Q2 FY27 revenue from operations of ₹659 crore, up 23% YoY, driven by broad-based CRO and CDMO growth. Q2 EBITDA rose 20% YoY to ₹187 crore with a 28% margin, while PAT grew 17% YoY to ₹98 crore. For H1 FY27, revenue reached ₹1,213 crore (+17% YoY), EBITDA rose to ₹335 crore (+19% YoY), and PAT reached ₹172 crore (+19% YoY). The company invested ₹621 crore in capex during H1 FY27 and expects a stronger second half.
Original exchange filing (PDF)
More announcements from Sai Life Sciences Ltd
- Upgradation in the Credit Rating by India Rating & Research Pvt. Ltd. · 14 Nov 2026
- Transcripts of Earnings call organized on 06th November 2026 · 12 Nov 2026
- Monitoring Agency Report for the Quarter ended 30th September 2026 · 12 Nov 2026
- Audio Recording of Earnings call for Q-2 FY 2026-27 · 06 Nov 2026
- Investor Presentation on Q-2 FY 2026-27 Financial Results · 06 Nov 2026
- Allotment of 1,08,005 Equity having Face Value of Rs.1/- against the options exercised in accordance with the Companies ESOP Plans · 06 Nov 2026
- Sai Life Sciences Limited has informed the Exchange regarding Allotment of 108005 Shares. · 06 Nov 2026
- Change In Management - Appointment of SMPs · 06 Nov 2026
